中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.017 seconds)

    ANTI-PRLR ANTIBODIES AND USES THEREOF
    5.
    发明申请
    ANTI-PRLR ANTIBODIES AND USES THEREOF 审中-公开
    抗PRLR抗体及其用途

    公开(公告)号：WO2015026907A1

    公开(公告)日：2015-02-26

    申请号：PCT/US2014/051831

    申请日：2014-08-20

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： PAPADOPOULOS, Nicholas ,  THURSTON, Gavin ,  KIRSHNER, Jessica ,  KELLY, Marcus ,  NITTOLI, Thomas ,  DELFINO, Frank

    IPC: C07K16/28 ,  A61K47/48 ,  A61P35/00

    CPC classification number: C07K16/2866 ,  A61K31/537 ,  A61K47/6803 ,  A61K47/6849 ,  A61K2039/505 ,  C07K16/2869 ,  C07K2317/21 ,  C07K2317/24 ,  C07K2317/52 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/76 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2317/94

    Abstract: The present disclosure provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the disclosure bind human PRLR with high affinity. In certain embodiments, the disclosure includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the disclosure includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the disclosure may be fully human antibodies. The disclosure includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the disclosure are useful for the treatment of various cancers as well as other PRLR-related disorders. The present disclosure also includes antibody drug conjugates comprising an antibody or antigen-binding fragment thereof that specifically binds a class I cytokine receptor, wherein the antibody or antigen-binding fragment thereof is conjugated to a cytotoxic agent.

    Abstract translation: 本公开提供了结合催乳素受体（PRLR）的抗体及其使用方法。 根据某些实施方案，本公开的抗体以高亲和力结合人PRLR。 在某些实施方案中，本公开包括结合PRLR并阻断催乳素介导的细胞信号传导的抗体。 在其它实施方案中，本公开包括结合PRLR但不阻断催乳素介导的细胞信号传导的抗体。 本公开的抗体可以是完全人抗体。 本公开内容包括与细胞毒性剂，放射性核素或对细胞生长或增殖有害的其它部分缀合的抗PRLR抗体。 本公开的抗体可用于治疗各种癌症以及其它PRLR相关疾病。 本公开还包括抗体药物缀合物，其包含特异性结合I类细胞因子受体的抗体或其抗原结合片段，其中抗体或其抗原结合片段与细胞毒性剂缀合。

    ANTI-MUC16 (MUCIN 16) ANTIBODIES
    7.
    发明申请
    ANTI-MUC16 (MUCIN 16) ANTIBODIES 审中-公开
    抗-MUC16（粘蛋白16）抗体

    公开(公告)号：WO2018058003A1

    公开(公告)日：2018-03-29

    申请号：PCT/US2017/053114

    申请日：2017-09-22

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： HABER, Lauric ,  SMITH, Eric ,  KELLY, Marcus ,  KIRSHNER, Jessica R. ,  COETZEE, Sandra ,  CRAWFORD, Alison ,  NITTOLI, Thomas ,  LIU, Yashu

    IPC: C07K16/30 ,  A61K39/395 ,  C07K16/44 ,  C07K16/28 ,  C07K16/46

    Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human andMUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16. The bispecific antigen-binding molecules of the invention are useful for the treatment of diseases and disorders in which an upregulated or induced MUC16-targeted immune response is desired and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of various cancers, including ovarian cancer. The present invention also includes anti-MUC16 antibody drug conjugates which inhibit tumor growth in vivo. In some embodiments, the anti-MUC16 antibodies are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.

    Abstract translation: 粘蛋白16（MUC16）在卵巢癌中高度表达，并且癌细胞上的表达显示出保护肿瘤细胞免受免疫系统的影响。 本发明提供结合人和MUC16的新型全长人IgG抗体（单特异性抗体）。 本发明还提供了新的双特异性抗体（bsAb），其在MUC16表达存在的肿瘤的存在下结合MUC16和CD3并经由CD3复合物活化T细胞。 根据某些实施方案，本发明提供了双特异性抗原结合分子，其包含特异性结合人和猴CD3的第一抗原结合结构域和特异性结合人和猴MUC16的第二抗原结合分子。 在某些实施方案中，本发明的双特异性抗原结合分子能够抑制表达MUC16的肿瘤的生长。 本发明的双特异性抗原结合分子可用于治疗需要上调或诱导的MUC16靶向的免疫应答和/或治疗有益的疾病和病症。 例如，本发明的双特异性抗体可用于治疗各种癌症，包括卵巢癌。 本发明还包括抑制体内肿瘤生长的抗-MUC16抗体药物缀合物。 在一些实施方案中，抗MUC16抗体可用于鉴定组织和/或血浆样品中MUC16存在的诊断方法。

Patent Agency Ranking